AZD4573 Is a Highly Selective CDK9 Inhibitor That Suppresses MCL-1 and Induces Apoptosis in Hematologic Cancer Cells.
Justin CidadoScott BoikoTheresa ProiaDouglas FergusonSteven W CriscioneMaryann San MartinPetar Pop-DamkovNancy SuValar Nila Roamio FranklinChandra Sekhar Reddy ChilamakuriClive S D'SantosWenlin ShaoJamal C SaehRaphael KochDavid M WeinstockMichael ZindaStephen E FawellLisa DrewPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
Selective targeting of CDK9 enables the indirect inhibition of MCL-1, providing a therapeutic option for MCL-1-dependent diseases. Accordingly, AZD4573 is currently being evaluated in a phase I clinical trial for patients with hematologic malignancies (clinicaltrials.gov identifier: NCT03263637).See related commentary by Alcon et al., p. 761.